CIT, a leading European non-clinical CRO, has announced that it will hold a symposium on innovative therapeutics in Paris, France, on June 3 and 4, 2010. The CIT International Scientific Symposium entitled 'New Developments in Safety Assessment' will be held at the Paris Yacht Club and involve speakers from France, the rest of Europe and the United States.
CIT is launching this symposium to offer a thorough update in key areas of research while emphasizing its research-driven credentials and demonstrating its leadership in innovative therapeutics.
CIT has designed the meeting to cover the latest trends in testing the safety of new therapeutics, how these requirements evolved and concerns that have been raised. Participants will have the opportunity to learn about three key areas: New perspectives in anticancer drug development; new approaches in ocular therapy and their safety assessment; and translational medicine, translational toxicology: new tools for bridging with the safety evaluation.
New generations of anti-cancer drugs are being developed using innovative therapeutic approaches. The symposium will review the latest international guidance on how these agents should be tested.
Delegates will also learn how to assess the safety of new eye medicines and the specific needs, specialist know-how and techniques involved.
Lastly, the meeting will review the latest scientific tools to evaluate the safety of drugs and propel their launch onto the market. Speakers will discuss progress in identifying biomarkers, signatures and measurements that can be used at every stage of drug development, from the early discovery phase to the registration.
"In order to work most effectively together, CIT and our clients need to be well informed and up to date with the latest technology and regulation involved in the safety testing of new therapeutics," said Jean-François Le Bigot, CIT's executive president. "We are delighted and honoured that leading figures from France, the rest of Europe and the US have agreed to participate in our symposium and we look forward to a couple of rich and productive days of discussion," he added.